• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Empower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare

    11/4/24 3:11:06 PM ET
    $AMZN
    $JNJ
    $ORCL
    $SNOW
    Catalog/Specialty Distribution
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMZN alert in real time by email

    BOWIE, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Inovalon, a leading provider of cloud-based software solutions empowering data-driven healthcare, welcomed industry trailblazers and visionary executives to the stage at Empower 2024, sparking meaningful conversations with leaders from every corner of healthcare. The annual summit, focused on the intersection of healthcare and technology, welcomed attendees in Washington, D.C., to showcase innovative strategies aimed at improving clinical, financial, and operational performance.

    Kicking off the summit, Keith Dunleavy, M.D., CEO and Founder of Inovalon, brought attendees through a technological innovation journey to highlight AI, machine learning, and data's impact on healthcare. Dunleavy shared, "We have an opportunity to make healthcare better, but we need to fully embrace the rapid progression of software sophistication and technology. We need to be willing to take on innovation at a faster, more uncomfortable pace."

    Applying AI in Healthcare, Today and Tomorrow



    AI innovation took center stage at Empower, with many sessions illustrating its transformative potential across the healthcare ecosystem. Industry leaders Rajesh Viswanathan, CTO at Inovalon, Rahul Pathak, VP of Gen AI and AI/ML GTM at AWS (NASDAQ:AMZN), Vinod Mamtani, VP, AI and Data Science Services at Oracle Cloud Infrastructure (NYSE:ORCL), and Murali Gandhirajan, Global Healthcare CTO at Snowflake (NYSE:SNOW), shared their perspectives on where the biggest opportunities in technology exist and their vision for how AI will unfold in the future of healthcare. The panel agreed that AI is a powerful force multiplier poised to personalize care interactions, automate workflows, and accelerate drug development. But they were clear: organizations must lean into these advancements or risk being left behind, and as the industry embraces emerging technology to assist, augment, and accelerate outcomes, those who commit will lead the way in delivering more efficient, impactful care.

    Modernizing the Healthcare System

    Former CDC Director, Rochelle Walensky, M.D., MPH, joined Inovalon's Chief Medical Officer, Dr. Paige Killian, M.D., on stage at Empower to advocate for data modernization across the healthcare and public health systems. Dr. Walensky provided first-hand perspective on the data challenges that the U.S. public health infrastructure faced during the pandemic and other outbreaks while she worked in the CDC and the difficulties with collecting and integrating a vast amount of data from various sources and formats in a timely manner. She emphasized that to get actionable data before we get past the peak of an outbreak or even the next pandemic, we must educate and upskill the healthcare workforce in data analysis and AI. This emphasis on the role of the healthcare and public health workforce in data modernization was a recurring theme throughout the conference, with all participants and speakers agreeing that a modern data strategy serves as the foundation for any successful public health, AI, or technology strategy.

    Maximizing Real-World Evidence and Utilizing SDOH Data to Improve Outcomes



    An additional theme at Empower was the benefit of unlocking real-world evidence (RWE) and social drivers of health (SDOH) data to create a more equitable healthcare ecosystem. While clinical trials are essential for determining drug safety and efficacy, they are prone to gaps in understanding the patient's experience and real-world outcomes. Industry experts, including Christie Teigland, Ph.D., VP of Research Science & Advanced Analytics at Inovalon, Todd Sharp, Head of Strategy & Transformation for Healthcare and Life Sciences at AWS (NASDAQ:AMZN), and Brett Kay, Director of Healthcare Quality Strategy at Johnson & Johnson (NYSE:JNJ), shared strategies for activating RWE and SDOH data to support vulnerable and underrepresented populations. With SDOH contributing to up to 80% of health outcomes, these sessions highlighted opportunities for leveraging data to bridge care gaps and improve cross-industry collaboration. But first, it was clear there must be a push to reduce disparate data sources, improve health literacy, and actively fight against health disparities to improve representation and care across the healthcare continuum.

    The Future of Patient-Centric Cell and Gene Therapies



    Cell and gene therapies have transformed how the healthcare industry treats and potentially cures common and rare diseases. Kim Tedesco, RPh, Director of Gene & Cell Therapy Pharmacy Operations at Walgreens (NASDAQ:WBA), welcomed to the Empower stage the first patient to ever receive a CRISPR cell-based gene therapy treatment for sickle cell. The patient advocate brought attendees through her care and treatment journey while living with the crippling disease through childhood and adulthood. The session highlighted the miracles of these therapies and the essential relationships between pharmacies, providers, and health plans needed to ensure patients receive life-saving treatments.

    Advancing Data-Driven Healthcare: Seven New Software Solutions and Feature-Set Expansions Announced

    In a continued effort to drive ever-greater impact across the healthcare continuum, Inovalon unveiled seven new products and features to help providers, payers, pharmacies, and life sciences prioritize data-driven healthcare.

    The Eligibility Verification Pro solution improves revenue cycle management by simplifying providers' ability to accurately verify patients' insurance coverage, reducing claims denials, and improving cash flow. For health plans, Inovalon announced Converged Provider Enablement to turn cost and utilization data into actionable insights, Converged Record Review to automate manual medical record reviews and improve risk score accuracy, and Converged Outreach Connectors to provide secure, seamless member data sharing capabilities. Additionally, the company also launched a Research Network to help health systems and life sciences organizations accelerate access to clinical trials and life-saving therapies. Finally, Inovalon is expanding the feature set of ScriptMed and debuted the new Inovalon Application Portal to provide customers with a centralized hub to find and launch all Inovalon ONE® Platform applications.

    Additional details on the product news can be found on Inovalon's website here: https://www.inovalon.com/news/inovalon-launches-seven-new-software-solutions-and-feature-set-expansions-to-drive-ever-greater-impact-across-the-healthcare-continuum/.

    "Empower 2024 showed us that the technology revolution poised to transform healthcare isn't lifetimes away – it's right around the corner," said Eron Kelly, President of Inovalon. "Inovalon is leading the charge in data-driven healthcare transformation. Together, with our customers and partners, we are shifting from a reactive, episodic industry to a more predictive and preventive system where data, AI, and personalization are shaping the future of healthcare."

    Experience Empower 2024's best moments here: https://www.inovalon.com/empower/.





    About Inovalon

    Inovalon is a leading provider of cloud-based SaaS solutions empowering data-driven healthcare. The Inovalon ONE® Platform brings together national-scale connectivity, real-time primary source data access, and advanced analytics into a sophisticated cloud-based platform empowering improved outcomes and economics across the healthcare ecosystem. The company's analytics and capabilities are used by nearly 20,000 customers supporting more than 53,000 sites of care, and are informed by the primary source data of more than 85 billion medical events across 1.1 million physicians, 677,000 clinical settings, and 395 million unique lives. For more information, visit www.inovalon.com.

    Contact:

    Tom Paolella

    Sr. Director, Press and Analyst Relations, Inovalon

    [email protected]



    Primary Logo

    Get the next $AMZN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMZN
    $JNJ
    $ORCL
    $SNOW

    CompanyDatePrice TargetRatingAnalyst
    Johnson & Johnson
    $JNJ
    10/20/2025$203.00Neutral → Outperform
    Daiwa Securities
    Oracle Corporation
    $ORCL
    10/13/2025$345.00 → $355.00Outperform
    BMO Capital Markets
    Oracle Corporation
    $ORCL
    10/9/2025$365.00Outperform
    Robert W. Baird
    Johnson & Johnson
    $JNJ
    10/3/2025$212.00Equal Weight → Overweight
    Wells Fargo
    Amazon.com Inc.
    $AMZN
    10/3/2025$240.00 → $275.00Buy
    Goldman
    Snowflake Inc.
    $SNOW
    10/1/2025$275.00Overweight
    Wells Fargo
    Amazon.com Inc.
    $AMZN
    9/30/2025$300.00Outperform
    Mizuho
    Oracle Corporation
    $ORCL
    9/25/2025$175.00Sell
    Rothschild & Co Redburn
    More analyst ratings

    $AMZN
    $JNJ
    $ORCL
    $SNOW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Johnson & Johnson upgraded by Daiwa Securities with a new price target

    Daiwa Securities upgraded Johnson & Johnson from Neutral to Outperform and set a new price target of $203.00

    10/20/25 8:00:27 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BMO Capital Markets reiterated coverage on Oracle with a new price target

    BMO Capital Markets reiterated coverage of Oracle with a rating of Outperform and set a new price target of $355.00 from $345.00 previously

    10/13/25 8:34:17 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Robert W. Baird initiated coverage on Oracle with a new price target

    Robert W. Baird initiated coverage of Oracle with a rating of Outperform and set a new price target of $365.00

    10/9/25 8:28:15 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    $AMZN
    $JNJ
    $ORCL
    $SNOW
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 11, 2025 - FDA Roundup: March 11, 2025

    For Immediate Release: March 11, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:Today, the FDA published a General Correspondence Letter issued to Mid-Link Technology Testing Co., Ltd. The FDA is vigilant in ensuring data submitted to the FDA can be relied upon to assess the effectiveness, safety, or risk of a device. The FDA has noted an incr

    3/13/25 3:14:00 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    November 14, 2023 - FDA Roundup: November 14, 2023

    For Immediate Release: November 14, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA updated the advisory for the Investigation of Elevated Lead Levels in Cinnamon Applesauce Pouches to include an expanded recall from WanaBana LLC to include Weis and Schnucks-brand cinnamon applesauce pouches. As of November 13, 2023, there

    11/14/23 3:26:18 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    September 12, 2023 - FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products

    For Immediate Release: September 12, 2023 The U.S. Food and Drug Administration has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. These warning letters are part of the agency’s ongoing effort to protect Americans from potentially harmful ophthalmic products. Eye products addressed in the eight warning letters are illegal

    9/12/23 10:44:21 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $AMZN
    $JNJ
    $ORCL
    $SNOW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $AMZN
    $JNJ
    $ORCL
    $SNOW
    SEC Filings

    View All

    $AMZN
    $JNJ
    $ORCL
    $SNOW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $AMZN
    $JNJ
    $ORCL
    $SNOW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fairhead Rona Alison bought $112,258 worth of shares (480 units at $233.87), increasing direct ownership by 2% to 22,110 units (SEC Form 4)

    4 - ORACLE CORP (0001341439) (Issuer)

    7/9/25 4:39:51 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Executive Chairman of Board Pessina Stefano sold $9,163,161 worth of shares (832,258 units at $11.01) and bought $9,163,161 worth of shares (832,258 units at $11.01), decreasing direct ownership by 56% to 657,308 units (SEC Form 4)

    4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

    4/29/25 8:49:21 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Boskin Michael J bought $111,145 worth of shares (1,682 units at $66.08), increasing direct ownership by 2% to 92,458 units (SEC Form 4)

    4 - ORACLE CORP (0001341439) (Issuer)

    3/21/25 8:43:30 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    SEC Form 144 filed by Snowflake Inc.

    144 - Snowflake Inc. (0001640147) (Subject)

    10/16/25 10:26:07 AM ET
    $SNOW
    Computer Software: Prepackaged Software
    Technology

    Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - JOHNSON & JOHNSON (0000200406) (Filer)

    10/14/25 7:22:58 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 8-K/A filed by Oracle Corporation

    8-K/A - ORACLE CORP (0001341439) (Filer)

    10/6/25 4:15:26 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Sunnybrook Health Sciences Centre Selects Oracle Health Technology to Enhance Patient and Caregiver Experiences

    New AI-powered EHR will replace multiple information systems and connect care teams across the hospital system to provide high-quality care AUSTIN, Texas, Oct. 20, 2025 /PRNewswire/ -- Sunnybrook Health Sciences Centre chose Oracle Health as its technology vendor of choice for its new electronic health record (EHR) system. With a new health information system powered by Oracle Health's next-generation, AI-powered EHR, Sunnybrook aims to increase insight at the point of care and enhance coordination across facilities to deliver more integrated patient experiences. Sunnybrook is

    10/20/25 9:00:00 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Oracle Enhances Public Safety Suite for Real-Time Data Intelligence

    AI-driven analytics and voice commands, and wearable computer system help first responders improve efficiency, situational awareness, and issue resolution DENVER, Oct. 20, 2025 /PRNewswire/ -- IACP Annual Conference and Exposition – Oracle today announced enhancements to its Oracle Public Safety Suite, a unified hardware and software platform for law enforcement and first responders. Updated features include officer-worn cameras and AI-enabled mobile voice controls and insights that improve situational awareness and help first responders make safer, more objective decisions when every second counts.

    10/20/25 8:00:00 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Minnesota First Responder Agency Modernizes Public Safety with Oracle

    Wright County Sheriff's Office adopts Oracle real-time video and recording capabilities, enhancing AI-based situational awareness and accountability DENVER, Oct. 20, 2025 /PRNewswire/ -- IACP Annual Conference and Exposition –  Minnesota's Wright County Sheriff's Office is leveraging the Oracle Public Safety Wearable Computer System to enhance officer safety and community trust. The AI-powered, officer-worn devices automatically record interactions and, after the next phase, are planned to stream high-quality, live footage to the office command center to deliver real-time situational awareness during incidents. Following the complete deployment of Oracle's officer-worn system, Wright County

    10/20/25 8:00:00 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    EVP, Chief Legal Officer Levey Stuart sold $5,927,400 worth of shares (19,758 units at $300.00), decreasing direct ownership by 52% to 18,429 units (SEC Form 4)

    4 - ORACLE CORP (0001341439) (Issuer)

    10/14/25 8:29:39 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Chief Financial Officer Robins Brian G was granted 149,058 shares (SEC Form 4)

    4 - Snowflake Inc. (0001640147) (Issuer)

    10/10/25 7:28:50 PM ET
    $SNOW
    Computer Software: Prepackaged Software
    Technology

    EVP, Product Management Kleinerman Christian sold $1,250,000 worth of shares (5,000 units at $250.00) (SEC Form 4)

    4 - Snowflake Inc. (0001640147) (Issuer)

    10/10/25 7:28:10 PM ET
    $SNOW
    Computer Software: Prepackaged Software
    Technology

    $AMZN
    $JNJ
    $ORCL
    $SNOW
    Leadership Updates

    Live Leadership Updates

    View All

    Health Systems Simplify Secure Data Exchange with Oracle Health

    New Oracle Health Connection Hub delivers single, unified console to enable data sharing control, auditing, and governance so health systems can easily manage a broad range of interoperability services Early adopters see 50 percent reduction in processing times of Social Security Administration disability benefit claims AUSTIN, Texas, Oct. 9, 2025 /PRNewswire/ -- Oracle Health Connection Hub is now generally available for U.S. healthcare providers, enabling them to use a single console to more easily onboard, access, and manage preferences for Oracle Health interoperability solutions. The latest step in Oracle's strategy to increase interoperability and reduce friction between payers and pr

    10/9/25 9:00:00 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o

    9/25/25 4:15:00 PM ET
    $JNJ
    $RBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

    Johnson & Johnson (NYSE:JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908666514/en/John Morikis headshot "We are pleased to welcome John to our Company's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is a proven leader of a large multinational organization who possesses a strong understanding of global markets and complex supply chains. His unique perspective and ability to harness technology to driv

    9/8/25 6:17:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMZN
    $JNJ
    $ORCL
    $SNOW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Snowflake Inc.

    SC 13G/A - Snowflake Inc. (0001640147) (Subject)

    11/12/24 5:50:12 PM ET
    $SNOW
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by Amazon.com Inc.

    SC 13G/A - AMAZON COM INC (0001018724) (Subject)

    11/8/24 4:33:15 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Amazon.com Inc.

    SC 13G/A - AMAZON COM INC (0001018724) (Filed by)

    11/7/24 5:23:12 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    $AMZN
    $JNJ
    $ORCL
    $SNOW
    Financials

    Live finance-specific insights

    View All

    Amazon.com to Webcast Third Quarter 2025 Financial Results Conference Call

    Amazon.com, Inc. (NASDAQ:AMZN) announced today that it will hold a conference call to discuss its third quarter 2025 financial results on Thursday, October 30, 2025, at 2:00 p.m. PT/5:00 p.m. ET. The event will be webcast live, and the audio and associated slides will be available for at least three months thereafter at www.amazon.com/ir. View source version on businesswire.com: https://www.businesswire.com/news/home/20251016136519/en/ Amazon.com Public Relations [email protected] amazon.com/ir

    10/16/25 4:01:00 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2025

    Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2025 of $1.30 per share on the company's common stock. The dividend is payable on December 9, 2025 to shareholders of record at the close of business on November 25, 2025. The ex-dividend date is November 25, 2025. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquel

    10/14/25 6:30:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Announces Intent to Separate Its Orthopaedics Business

    Strengthens focus of Johnson & Johnson as an innovation powerhouse and accelerates the portfolio shift of its MedTech Segment to higher-growth and higher-margin markets Standalone orthopaedics business would operate as DePuy Synthes and be the largest, most comprehensive orthopaedics-focused company in the world Namal Nawana appointed to serve as Worldwide President of DePuy Synthes Johnson & Johnson (the "Company") (NYSE:JNJ) today announced the Company's intent to separate its Orthopaedics business to enhance the strategic and operational focus of each company and drive value for stakeholders. The intended separation would further strengthen the focus of Johnson & Johnson as an in

    10/14/25 6:21:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care